Description: Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, acne, rosacea, and psoriasis; and central nervous system, cardiovascular, and gastrointestinal diseases. Its strategic brands include ACTIKERALL, BALNEUM, DECODERM, SATIVEX, SKILARENCE, and DECODERM. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases, as well as drug discovery partnership with X-Chem, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Home Page: www.almirall.com
Ronda Del General Miter, 151
Barcelona,
08022
Spain
Phone:
34 93 291 30 00
Officers
| Name | Title |
|---|---|
| Mr. Carlos Gallardo Piqué | Interim CEO & Pres of the Board |
| Mr. Michael McClellan | Exec. VP of Fin., CFO & Member of Management Board |
| Mr. Joan Figueras Carreras | Vice Sec., Member of Mgmt. Board, Non-Voting Director & Exec. Director of Corp. Governance |
| Mr. Eloi Crespo Cervera | Sr. VP of Industrial Operations & Member of Management Board |
| Mr. Jordi Sabé Richer | Sr. VP of Corp. Devel. & Member of Management Board |
| Mr. Esteve Conesa Panicot | Sr. VP of HR & Member of Management Board |
| Dr. Volker Koscielny | Chief Medical Officer & Member of Management Board |
| Mr. Pablo Alvarez | Member of Management Board, Pres of Almirall US & GM of Almirall US |
| Dr. Karl Ziegelbauer | Exec. VP of R&D, CSO and Member of Management Board |
| Mr. Paolo Cionini | Chief Commercial Officer Europe & International and Member of Management Board |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 29.4118 |
|---|---|
| Trailing PE: | 56.9412 |
| Price-to-Book MRQ: | 1.2299 |
| Price-to-Sales TTM: | 2.0344 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1786 |